General MedicationsORALGeneric
EXELON
RIVASTIGMINE TARTRATE
Standard Dose
EQ 2MG BASE/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview EXELON is listed in Drugs@FDA under application 021025 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient RIVASTIGMINE TARTRATE Form and strength SOLUTION;ORAL - EQ 2MG BASE/ML Sponsor NOVARTIS Submission history Latest submission status date: 2018-12-18 00:00:00.
Structured Monograph
Clinical summary
Approval overview EXELON is listed in Drugs@FDA under application 021025 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient RIVASTIGMINE TARTRATE Form and strength SOLUTION;ORAL - EQ 2MG BASE/ML Sponsor NOVARTIS Submission history Latest submission status date: 2018-12-18 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.